Volume 18 Number 9
30 September 2016

Home > Publications > Current Neuro-Oncology > Volume 18, Year 2016 > Number 9, 30 September

Zhang Z, Li C, Tan Q, Xie C, Yang Y, Zhan W, Han F, Sharma HS, Sharma A.
Curcumin suppresses tumor growth and angiogenesis in human glioma cells through modulation of vascular endothelial growth factor/angiopoietin-2/thrombospondin-1 signaling.
CNS Neurol Disord Drug Targets. 2016 Sep 2, 2017;16(3):346-350
. doi: 10.2174/1871527315666160902144513. PMID: 27592626. Laboratory investigation; ˍ

Schnell O, Thorsteinsdottir J, Fleischmann DF, Lenski M, Abenhardt W, Giese A, Tonn JC, Belka C, Kreth FW, Niyazi M.
Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
J Neurooncol. 2016 Sep 6, 2016;130(3):591-599
. doi: 10.1007/s11060-016-2267-x. PMID: 27599828. Observational study. ˍ

Hofmaier J, Kantz S, Söhn M, Dohm OS, Bächle S, Alber M, Parodi K, Belka C, Niyazi M.
Hippocampal sparing radiotherapy for glioblastoma patients: a planning study using volumetric modulated arc therapy.
Radiat Oncol. 2016 Sep 8, 2016;11(1):118
. doi: 10.1186/s13014-016-0695-6. PMID: 27609371. Observational study. ˍ

Moller S, Law I, Munck Af Rosenschold P, Costa J, Poulsen HS, Engelholm SA, Engelholm S.
Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial.
Radiother Oncol. 2016 Sep 9, 2016;121(1):132-137
. doi: 10.1016/j.radonc.2016.08.014. PMID: 27622554. Interventional study. ˍ

Bryan RN.
Science to Practice: Can Focused Ultrasound Disruption of the Blood-Brain Barrier Improve Malignant Brain Tumor Treatment Outcomes?
Radiology. 2026 Sep 19, 2016;281(1):1-3
. doi: 10.1148/radiol.2016161363. PMID: 27643762. Comment. ˍ
Refers to: Liu HL, et al., Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment.
Radiology. 2016 May 18, 2016;281(1):99-108
. doi: 10.1148/radiol.2016152444. PMID: 27192459. Laboratory investigation. ˍ

van West SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, van den Bent MJ, Taal W.
Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
Neuro Oncol. 2016 Sep 21, 2017;19(5):719-725
. doi: 10.1093/neuonc/now194. PMID: 28453748. Observational study. ˍ

Villani V, Merola R, Vidiri A, Fabi A, Carosi M, Giannarelli D, Marucci L, Maschio M, Carapella CM, Pace A.
Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
Tumori. 2016 Sep 22, 2017;103(3):255-260
. doi: 10.5301/tj.5000565. PMID: 27716874. Interventional study. ˍ

Bouffet E, Ramaswamy V.
Old chemotherapy makes a comeback: dual alkylator therapy for pediatric high-grade glioma.
Neuro Oncol. 2016 Sep 23, 2016;18(10):1333-4
. doi: 10.1093/neuonc/now200. PMID: 27664858. Editorial. ˍ
Refers to: Jakacki RI, et al., Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Neuro Oncol. 2016 Mar 22, 2016;18(10):1442-50
. doi: 10.1093/neuonc/now038. PMID: 27006176. Interventional study. ˍ

Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJ, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
Neuro Oncol. 2016 Sep 23, 2017;19(5):669-677
. doi: 10.1093/neuonc/now208. PMID: 28453749. Observational study. ˍ

Chaturvedi J, Nandeesh BN, Srinivas D, Mahadevan A, Sampath S.
Synchronous Pediatric Supratentorial Glioblastoma Multiforme with Noncontiguous Infratentorial Pilocytic Astrocytoma: A Rare Event.
J Neurosci Rural Pract. 2016 Sep 25, 2016;7(Suppl 1):S120-S122
. doi: 10.4103/0976-3147.196446. PMID: 28163525. Letter to the Editor. ˍ

Satyarthee GD, Sudhan MD, Mehta VS.
Pilocytic Midbrain Astrocytoma Presenting with Fresh Bleed after Twenty-one-years Survival Following First Surgery: A Unique Case of Longest Brainstem Glioma Survival.
J Neurosci Rural Pract. 2016 Sep 25, 2016;7(Suppl 1):S88-S90
. doi: 10.4103/0976-3147.196452. PMID: 28163514. Case report. ˍ

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJ, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol. 2016 Sep 26, 2016;17(11):1521-1532
. doi: 10.1016/S1470-2045(16)30313-8. PMID: 27686946. Interventional study. ˍ

Reijneveld JC, Taphoorn MJ, Coens C, Bromberg JE, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG.
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol. 2016 Sep 26, 2016;17(11):1533-1542
. doi: 10.1016/S1470-2045(16)30305-9. PMID: 27686943. Interventional study. ˍ

Kong DS, Nam DH, Kang SH, Lee JW, Chang JH, Kim JH, Lim YJ, Koh YC, Chung YG, Kim JM, Kim CH.
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea.
Oncotarget. 2016 Sep 27, 2017;8(4):7003-7013
. doi: 10.18632/oncotarget.12273. PMID: 27690294. Interventional study. ˍ

Acquaye AA, Vera E, Gilbert MR, Armstrong TS.
Clinical presentation and outcomes for adult ependymoma patients.
Cancer. 2016 Sep 28, 2017;123(3):494-501
. doi: 10.1002/cncr.30355. PMID: 27679985. Observational study. ˍ

Akasaki Y, Kikuchi T, Homma S, Koido S, Ohkusa T, Tasaki T, Hayashi K, Komita H, Watanabe N, Suzuki Y, Yamamoto Y, Mori R, Arai T, Tanaka T, Joki T, Yanagisawa T, Murayama Y.
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Cancer Immunol Immunother. 2016 Sep 29, 2016;65(12):1499-1509
. doi: 10.1007/s00262-016-1905-7. PMID: 27688162. Interventional study. ˍ

Mitamura K, Yamamoto Y, Kudomi N, Maeda Y, Norikane T, Miyake K, Nishiyama Y.
Intratumoral heterogeneity of 18F-FLT uptake predicts proliferation and survival in patients with newly diagnosed gliomas.
Ann Nucl Med. 2016 Sep 29. 2017;31(1):46-52
. doi: 10.1007/s12149-016-1129-0. PMID: 27686469. Observational study. ˍ

Sarma A, Sharma VP, Sarkar AB, Sekar MC, Samuel K, Geusz ME.
The circadian clock modulates anti-cancer properties of curcumin.
BMC Cancer. 2016 Sep 29, 2016;16(1):759
. doi: 10.1186/s12885-016-2789-9. PMID: 27680947. Laboratory investigation. ˍ

Trogrlić I, Trogrlić D, Trogrlić Z.
Treatment of progression of diffuse astrocytoma by herbal medicine: case report.
Afr J Tradit Complement Altern Med. 2016 Sep 29, 2016;13(6):1-4
. doi: 10.21010/ajtcam.v13i6.1. PMID: 28480352. Case report. ˍ